Brolucizumab meet endpoints in diabetic macular edema phase 3 trial
Beovu (brolucizumab) 6 mg demonstrated non-inferiority versus aflibercept 2 mg in mean change in best-corrected visual acuity (BCVA) at year 1 in patients with diabetic macular edema (DME), according to clinical trial results released by Novartis.
The ongoing phase 3 KITE study is assessing the efficacy and safety of brolucizumab in 360 patients with DME.
“Living with DME has significant impact on patients’ lives and frequent treatment injections are needed to control the increased fluid in the eye,” said Dirk Sauer, Global Head Development, Novartis Pharma Ophthalmology. “This data confirms our strong belief in Beovu as a potential therapy for DME patients, and if approved, will provide patients with a new treatment option to control their disease through better resolution of retinal fluid and CST reductions.”